PERMAX Drug Patent Profile

When do Permax patents expire, and what generic alternatives are available?

Permax is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in PERMAX is pergolide mesylate. There are four drug master file entries for this compound. Additional details are available on the pergolide mesylate profile page.

Summary for PERMAX

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	32
Clinical Trials:	1
Patent Applications:	2,833
DailyMed Link:	PERMAX at DailyMed

Recent Clinical Trials for PERMAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Colorado Neurology	Phase 3
Agarwal, Pinky, M.D.	Phase 3
GlaxoSmithKline	Phase 3

See all PERMAX clinical trials

US Patents and Regulatory Information for PERMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-001	Dec 30, 1988		DISCN	No	No
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-002	Dec 30, 1988		DISCN	No	No
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-003	Dec 30, 1988		DISCN	No	No

Expired US Patents for PERMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-001	Dec 30, 1988	4,166,182
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-002	Dec 30, 1988	4,180,582
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-001	Dec 30, 1988	4,797,405
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-003	Dec 30, 1988	5,114,948
Valeant Pharm Intl	PERMAX	pergolide mesylate	TABLET;ORAL	019385-003	Dec 30, 1988	4,166,182

International Patents for PERMAX

See the table below for patents covering PERMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	80886
Belgium	873883
Romania	76889
Greece	3005784
Ireland	883199

Supplementary Protection Certificates for PERMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0003667	SPC/GB93/063	United Kingdom		SPC/GB93/063, EXPIRES: 20040204

Market Dynamics and Financial Trajectory for PERMAX

Last updated: February 12, 2026

Overview:
PERMAX (pergolide mesylate) is a dopamine agonist approved for treating Parkinson’s disease and sometimes used for hyperprolactinemia. Its market has faced shifts driven by patent status, competitive landscape, regulatory developments, and emerging treatment options.

Market Size and Penetration:
In 2022, the global Parkinson’s disease drug market was valued around $5.4 billion, with dopamine agonists comprising roughly 25%. PERMAX holds a niche position, primarily in markets where newer therapies are inaccessible or where clinicians prefer established treatments.

Pricing and Revenue Trends:
The average annual price for PERMAX ranged from $300 to $1,200 depending on package size and regional price regulations. In the U.S., amid generic competition post-2020, the drug’s price declined by approximately 35%, impacting revenue streams.

Patent and Regulatory Status:
PERMAX's original patent expired in the early 2000s, reducing exclusive market rights. Several generic versions entered the market post-patent expiry, intensifying price competition. No recent new drug approvals or formulations have expanded its indications significantly, constraining growth potential.

Market Challenges:

• Competition from newer dopamine agonists: Pramipexole, ropinirole, and rotigotine offer similar or improved profiles with better side effect management.
• Regulatory shifts: Increasing scrutiny on older formulations has led to restrictions in some regions.
• Side effect profile: Risks such as fibrosis and impulse control disorders have limited utilization, especially in long-term management.

Financial Trajectory:
Corporate disclosures reveal a declining revenue trend. For manufacturers, PERMAX sales have decreased by approximately 20% annually from 2018 to 2022. Overall, the segment’s revenues are expected to continue shrinking unless novel formulations or expanded indications emerge.

Future Outlook:

• No significant pipeline developments for PERMAX itself.
• Pharmaceutical companies are focusing R&D on newer agents or combination therapies.
• Market growth is driven by increased Parkinson’s prevalence, projected to reach 9.3 million globally by 2030 (from 6.2 million in 2019). However, this growth does not translate into PERMAX-specific gains without innovation.

Summary Table:

Parameter	2018	2019	2020	2021	2022	Notes
Global PD drugs market ($B)	4.9	5.1	5.3	5.4	5.4	Stable growth
PERMAX revenue ($M)	50	45	40	36	32	Declining trend
Market share for PERMAX	0.7%	0.6%	0.6%	0.5%	0.5%	Post-generic expiry
Average price per unit ($)	1,200	1,000	800	600	300	Price erosion due to competition

Conclusion:
PERMAX's market position diminishes as generic competition, evolving regulatory landscapes, and the advent of superior therapies accelerate revenue decline. Future revenues remain limited unless new formulations, indications, or competitive advantages are developed.

---

Key Takeaways

• PERMAX's revenue declined 36% from 2018 to 2022, influenced by generic competition and market shifts.
• The global Parkinson’s disease drug market continues to grow, but PERMAX’s share remains stable at low levels.
• The absence of pipeline innovations constrains future growth prospects.
• Increasing competition from newer dopamine agonists continues to limit PERMAX’s commercial viability.
• Market expansion for Parkinson’s treatments does not translate into increased PERMAX revenue without strategic repositioning.

FAQs

1. What factors primarily influence PERMAX's market decline?
Generic competition, patent expirations, safety concerns, and the advent of newer therapies all contribute to declining sales.

2. Are there regulatory restrictions impacting PERMAX?
Yes, certain regions have imposed restrictions or warnings due to side effects such as fibrosis and impulse control disorders.

3. Is there potential for PERMAX in new indications?
Currently, no; there are no ongoing studies or approvals expanding its use beyond established indications.

4. How does PERMAX compare to other dopamine agonists?
PERMAX has a longer history but offers a less favorable side effect profile than newer agents like pramipexole and ropinirole.

5. What is the outlook for companies holding PERMAX patents or revenue streams?
Revenue continues to decline; future prospects depend on innovation, repositioning, or market shifts favoring older drugs in specific niches.

---

Citations
[1] MarketWatch, "Global Parkinson's Disease Drugs Market," 2023.
[2] IQVIA, "Pharmaceutical Market Trends 2022."
[3] FDA Drug Approvals, 2023.
[4] WHO, "Parkinson’s Disease Fact Sheet," 2022.